Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + BEAM
- Development stage
- Preclinical
- Lead developer
- BeiGene
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Zanubrutinib + BEAM is a combination regimen consisting of the small molecule Bruton tyrosine kinase inhibitor zanubrutinib and the high-dose chemotherapy conditioning protocol known as BEAM. Zanubrutinib selectively inhibits Bruton tyrosine kinase, disrupting B-cell receptor signaling and leading to apoptosis in malignant B cells. The BEAM regimen includes four chemotherapeutic agents—carmustine (BCNU), etoposide, cytarabine, and melphalan—used primarily as a conditioning treatment before autologous stem cell transplantation in lymphoma patients. This combination is being explored for relapsed or refractory lymphomas to enhance anti-tumor efficacy prior to stem cell transplant[5][6][8].
- Brand names
- Brukinsa
- Other names
- BCNU/etoposide/cytarabine/melphalancarmustine/etoposide/cytarabine/melphalan
02
Targets
TOP2A (DNA topoisomerase II)BTK (Bruton tyrosine kinase)DNADNA polymerase family
Beyond the preview
Go deeper on zanubrutinib + BEAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + BEAM.